By Counterforce Health Team in Ultomiris (ravulizumab) —

Myths vs. Facts: Getting Ultomiris (Ravulizumab) Covered by UnitedHealthcare in Washington

Answer Box: Getting Ultomiris Covered by UnitedHealthcare in Washington

Eligibility: UnitedHealthcare requires prior authorization for Ultomiris (ravulizumab) with step therapy—typically trying eculizumab first. Fastest path: Submit complete PA documentation including diagnosis confirmation (PNH flow cytometry, AChR+ for gMG, AQP4+ for NMOSD), vaccination records, and prior therapy failures. First step today: Gather meningococcal vaccination proof and contact your provider to initiate the prior authorization through UnitedHealthcare's provider portal. If denied, Washington's external review through an Independent Review Organization (IRO) has strong patient protections with 15-day decisions.

Table of Contents

Why Myths About Ultomiris Coverage Persist

Getting a $500,000+ annual medication like Ultomiris approved feels overwhelming, and misinformation spreads quickly in patient communities. UnitedHealthcare's complex prior authorization requirements, combined with Washington's unique insurance landscape, create confusion about what's actually required versus what people assume.

The stakes couldn't be higher—Ultomiris treats life-threatening conditions like PNH, aHUS, generalized myasthenia gravis, and NMOSD. When patients hear conflicting advice about coverage, they often delay necessary appeals or submit incomplete documentation, creating unnecessary barriers to care.

Let's separate fact from fiction with Washington-specific guidance for UnitedHealthcare members.

Myth vs. Fact: Common Misconceptions

Myth 1: "If my doctor prescribes Ultomiris, UnitedHealthcare has to cover it"

Fact: UnitedHealthcare requires prior authorization for Ultomiris through OptumRx, regardless of medical necessity. Your provider must submit specific documentation proving you meet coverage criteria, including step therapy requirements that typically mandate trying eculizumab first.

Why this matters: Even urgent prescriptions need PA approval. The process takes time, so start early.

Myth 2: "I can't get Ultomiris if I haven't tried Soliris (eculizumab) first"

Fact: While UnitedHealthcare's step therapy generally requires eculizumab first, exceptions exist for contraindications, prior intolerance, or clinical reasons why eculizumab isn't appropriate. Document these thoroughly in your PA request.

Washington advantage: If denied, Washington's external review process allows independent medical experts to override insurer step therapy requirements they find unreasonable.

Myth 3: "Vaccination requirements are just recommendations"

Fact: Meningococcal vaccination is absolutely mandatory before starting Ultomiris due to the FDA's boxed warning. UnitedHealthcare will not approve coverage without documented vaccination at least 2 weeks prior (or antibiotic prophylaxis if urgent).

Critical detail: You need both MenACWY and MenB vaccines according to current guidelines.

Myth 4: "Appeals take forever and rarely work"

Fact: In Washington, external reviews through Independent Review Organizations (IROs) must be completed within 15 days for standard cases, 72 hours for urgent situations. While specific success rates aren't published, Washington's database shows many overturned denials for rare disease medications.

Myth 5: "I need a specialist to handle my appeal"

Fact: While specialists help, you can successfully appeal UnitedHealthcare denials yourself. Washington provides appeal templates and the Office of the Insurance Commissioner offers free assistance at 1-800-562-6900.

Myth 6: "Medicare Advantage plans are easier for rare disease coverage"

Fact: UnitedHealthcare's Medicare Advantage plans actually showed higher-than-average denial rates (around 9% for prior authorizations in 2023). The same rigorous PA requirements apply regardless of plan type.

Myth 7: "Generic alternatives are available"

Fact: No generic version of Ultomiris exists. While biosimilar eculizumab may become available, Ultomiris has unique dosing advantages (every 8 weeks vs. every 2 weeks) that may support medical necessity arguments.

What Actually Influences UnitedHealthcare Approval

Required Clinical Documentation

For PNH: Flow cytometry confirming ≥5% PNH cells, transfusion history, and hemolysis markers (LDH levels).

For aHUS: Clinical diagnosis with exclusion of STEC-HUS (Ultomiris is not indicated for Shiga toxin-related HUS).

For Generalized Myasthenia Gravis: Positive anti-AChR antibody serology, MGFA Class II-IV classification, MG-ADL score ≥6.

For NMOSD: Positive anti-AQP4 antibody testing via validated assay.

Step Therapy Documentation

UnitedHealthcare typically requires documentation of:

  • Prior eculizumab use with inadequate response, intolerance, or contraindication
  • Specific clinical reasons why alternatives aren't appropriate
  • Treatment goals and expected outcomes with Ultomiris

Vaccination and Safety Requirements

  • Meningococcal vaccination (MenACWY and MenB) completed ≥2 weeks before treatment
  • Documentation of vaccination dates and lot numbers
  • Patient education about infection risks and warning signs

Avoid These Critical Mistakes

1. Incomplete Vaccination Documentation

The error: Submitting PA requests without verified meningococcal vaccination records. The fix: Obtain vaccination certificates with dates, lot numbers, and provider signatures before submitting any coverage request.

2. Missing Step Therapy Justification

The error: Not explaining why eculizumab isn't appropriate or hasn't worked. The fix: Document specific clinical reasons: prior treatment failures, contraindications, or compelling medical necessity for Ultomiris over alternatives.

3. Insufficient Diagnostic Proof

The error: Submitting requests without condition-specific lab results or antibody testing. The fix: Include flow cytometry reports for PNH, antibody titers for gMG/NMOSD, and complete diagnostic workups.

4. Wrong Submission Route

The error: Faxing requests instead of using UnitedHealthcare's online portal. The fix: Submit through the UnitedHealthcare Provider Portal for faster processing and tracking.

5. Giving Up After First Denial

The error: Accepting initial denials without appealing. The fix: Use Washington's robust appeals process—many denials are overturned with complete documentation.

From our advocates: We've seen patients successfully overturn UnitedHealthcare denials by focusing on three key elements: complete vaccination documentation, detailed step therapy justification, and condition-specific lab results. One composite case involved a Washington patient whose initial PNH denial was overturned within two weeks of external review after providing comprehensive flow cytometry data and eculizumab intolerance documentation.

Your 3-Step Action Plan

Step 1: Document Everything (Do This Today)

  • Gather insurance cards, policy numbers, and provider information
  • Collect all lab results confirming your diagnosis
  • Obtain vaccination records or schedule meningococcal vaccines immediately
  • Document any prior treatments tried and their outcomes

Step 2: Submit Complete Prior Authorization

  • Work with your provider to submit PA through UnitedHealthcare's online portal
  • Include medical necessity letter addressing step therapy requirements
  • Attach all required clinical documentation and vaccination proof
  • Request expedited review if medically urgent

Step 3: Prepare for Potential Appeal

  • Save all denial letters and correspondence
  • Research similar cases in Washington's IRO decision database
  • Contact the Office of the Insurance Commissioner for appeal guidance if needed
  • Consider Counterforce Health's platform for evidence-backed appeal assistance

Washington Appeals Process

Internal Appeals (First Step)

  • Timeline: UnitedHealthcare typically allows 180 days from denial
  • Process: Submit through member portal or provider portal
  • Documentation: Include all supporting medical evidence and step therapy justification

External Review (If Internal Appeal Fails)

Washington's Independent Review Organization process offers strong patient protections:

  • Timeline: 15 days for standard review, 72 hours for urgent cases
  • Process: Request through Office of the Insurance Commissioner or your insurer
  • Patient rights: 5 business days to submit additional evidence to the IRO
  • Outcome: IRO decision is binding on UnitedHealthcare

Contact: Washington Office of the Insurance Commissioner at 1-800-562-6900 for free appeal assistance.

When to Escalate

If external review fails, you may pursue legal action under ERISA Section 502(a) for employer-sponsored plans or contact the Office of the Insurance Commissioner for additional guidance.

Resources and Next Steps

Official Resources

Patient Support

  • Alexion Access Navigator for coverage assistance
  • Washington Healthplanfinder for plan comparisons
  • Office of the Insurance Commissioner Consumer Advocacy: 1-800-562-6900

Professional Support

For healthcare providers and patients dealing with complex denials, Counterforce Health specializes in turning insurance denials into targeted, evidence-backed appeals. Their platform analyzes denial letters, plan policies, and clinical notes to identify the specific denial basis and draft point-by-point rebuttals aligned to UnitedHealthcare's own rules, potentially saving months in the appeals process.

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies change frequently—always verify current requirements with UnitedHealthcare and consult healthcare providers for medical decisions. For personalized assistance with Washington insurance appeals, contact the Office of the Insurance Commissioner at 1-800-562-6900.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.